MAESTRO: A randomized, double-blind phase III study of evofosfamide (Evo) in combination with gemcitabine (Gem) in previously untreated patients (pts) with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC)

被引：25

作者：

Van Cutsem, Eric

Lenz, Heinz-Josef

Furuse, Junji

Tabernero, Josep

Heinemann, Volker

Ioka, Tatsuya

Bazin, Igor

Ueno, Makoto

Csoszi, Tibor

Wasan, Harpreet

Melichar, Bohuslav

Karasek, Petr

Macarulla, Teresa Mercade

Guillen, Carmen

Kalinka-Warzocha, Ewa

Horvath, Zsolt

Prenen, Hans

Schlichting, Michael

Ibrahim, Ayman

Bendell, Johanna C.

机构：

[1] Univ Hosp Leuven, Leuven, Belgium

[2] Univ Southern Calif, Los Angeles, CA USA

[3] Kyorin Univ, Dept Med Oncol, Sch Med, Tokyo, Japan

[4] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain

[5] Ludwig Maximilian Univ Munich, Ctr Comprehens Canc, Munich, Germany

[6] Osaka Med Ctr Canc & Cardiovasc Dis, Hepatobiliary & Pancreat Oncol, Osaka, Japan

[7] NN Blokhin Russian Canc Res Ctr, Moscow, Russia

[8] Kanagawa Canc Ctr, Div Hepatobiliary & Pancreat Oncol, Yokohama, Kanagawa, Japan

[9] Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz R, Szolnok, Hungary

[10] Imperial Coll, Hammersmith Hosp, London, England

[11] Palacky Univ, Med Sch & Teaching Hosp, Olomouc, Czech Republic

[12] Masaryk Mem Canc Inst, Brno, Czech Republic

[13] Vall dHebron Inst Oncol, Barcelona, Spain

[14] Ramon y Cajal Univ Hosp, Dept Med Oncol, IRYCIS, RETICC Spanish Minist Sci & Innovat, Madrid, Spain

[15] Reg Oncol Ctr, Lodz, Poland

[16] Univ Debrecen, Debrecen, Hungary

[17] Katholieke Univ Leuven, Univ Hosp Leuven, Dept Oncol, Digest Oncol Unit, Leuven, Belgium

[18] Merck KGaA, Darmstadt, Germany

[19] EMD Serono, Billerica, MA USA

[20] Sarah Cannon Res Inst, Nashville, TN USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期

关键词：

D O I：

10.1200/JCO.2016.34.15_suppl.4007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4007

引用

页数：2

共 50 条

[1] Evofosfamide (TH-302) in combination with gemcitabine in previously untreated patients with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma: Primary analysis of the randomized, double-blind phase III MAESTRO study.
Van Cutsem, Eric
Lenz, Heinz-Josef
Furuse, Junji
Tabernero, Josep
Heinemann, Volker
Ioka, Tatsuya
Bazin, Igor
Ueno, Makoto
Csoszi, Tibor
Wasan, Harpreet
Melichar, Bohuslav
Karasek, Petr
Macarulla, Teresa
Ponce, Carmen Guillen
Kalinka-Warzocha, Ewa
Horvath, Zsolt
Prenen, Hans
Schlichting, Michael
Mehdi, Fazal
Bendell, Johanna C.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
[2] Efficacy and safety of gemcitabine in combination with TH-302 compared with gemcitabine in combination with placebo in previously untreated patients with metastatic or locally advanced unresectable pancreatic adenocarcinoma: The MAESTRO trial
Van Cutsem, Eric
Fram, Robert J.
Schlichting, Michael
Ryan, David P.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[3] Evofosfamide combined with gemcitabine/nabpaclitaxel in patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma (PAC): Results of a phase I trial
Borad, Mitesh J.
Kwak, Eunice Lee
Wang-Gillam, Andrea
Ibrahim, Ayman
Aldridge, Julie
Olszanski, Anthony J.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[4] Phase I study of trifluridine/tipiracil in combination with gemcitabine (gem) and nabpaclitaxel (nab-P) in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC).
Turk, Anita Ahmed
Helft, Paul R.
Sehdev, Amikar
Shahda, Safi
Loehrer, Patrick J.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 731 - 731
[5] A phase II study of gemcitabine, oxaliplatin, and erlotinib (GEMOX-T) combination chemotherapy in previously untreated patients with locally advanced unresectable or metastatic pancreatic cancer
Yun, Jina
Kim, Han Jo
Kim, Kyoung Ha
Kim, Se Hyung
Kim, Hyun Jung
Lee, Sang-Cheol
Bae, Sang Byung
Kim, Chan Kyu
Lee, Namsu
Lee, Kyu Taek
Park, Soong Kyu
Won, Jong-Ho
Hong, Dae Sik
Park, Hoe Sook
Choi, Hyun Jong
Moon, Jong Ho
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[6] Efficacy and safety of sitagliptin, in combination with gemcitabine plus nab-paclitaxel (GnP) in patients with previously untreated advanced pancreatic ductal adenocarcinoma (PDAC)
Zhou, Tianxing, Sr.
Wang, Xiuchao, Sr.
Yang, Chao, Sr.
Yu, Jun, Sr.
Hao, Jihui
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[7] A phase 1/2 study of combination therapy of ivaltinostat, gemcitabine, and erlotinib in patients with unresectable, locally advanced and metastatic pancreatic adenocarcinoma
Jo, J.
Lee, H.
Park, S.
Chung, D.
Cho, S.
Cha, H.
Cho, J.
Song, S.
[J]. ANNALS OF ONCOLOGY, 2020, 31 : S211 - S211
[8] Phase I Dose-Finding Study of Vandetanib in Combination with Gemcitabine in Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma
Saletti, Piercarlo
Sessa, Cristiana
De Dosso, Sara
Cerny, Thomas
Renggli, Verena
Koeberle, Dieter
[J]. ONCOLOGY, 2011, 81 (01) : 50 - 54
[9] Dasatinib combined with gemcitabine (Gem) in patients (pts) with locally advanced pancreatic adenocarcinoma (PaCa): Design of CA180-375, a placebo-controlled, randomized, double-blind phase II trial
Evans, T. R. Jeffry
Van Cutsem, Eric
Moore, Malcolm J.
Purvis, Joseph D.
Strauss, Lewis C.
Rock, Edwin P.
Lee, Jennifer
Lin, Chihche
Rosemurgy, Alexander
Arena, Francis P.
Gara, Michelle
Armstrong, Elizabeth
O'Dwyer, Peter J.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[10] Phase II trial of preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by postoperative gemcitabine (GEM) in patients (pts) with borderline resectable (BR) and locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC)
Jeong, J. H.
Yoo, C.
Kim, K-P.
Chang, H-M.
Ryoo, B-Y.
[J]. ANNALS OF ONCOLOGY, 2019, 30 : 263 - 263

← 1 2 3 4 5 →